Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

A new study published in Biopsychosocial Science and Medicine suggests that a father’s psychological resilience may play a significant role in the biological health of his pregnant partner and the ...

This month, funded startups that caught our eye included a company aiming to make a better wireless monitor for heart disease ...

The results of a home pregnancy test aren't always black or white (or clearly blue or pink!). If you see a faint line on a pregnancy test, especially if you took the test correctly, you're probably ...

The increase in fitness testing aligns with Defense Secretary Pete Hegseth’s push for increased physical standards across the ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Adding tucatinib to standard first-line maintenance therapy in patients with HER2-positive metastatic breast cancer led to a clinically meaningful delay in disease progression, regardless of the ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...

NEW YORK, December 10, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part ...

Many medical organizations and frontline health care providers are grappling with a challenge they haven’t had to face in many years: how to protect newborns against hepatitis B. Last week, a federal ...